Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q2
Sell
-54
Closed -$3.97K 298
2023
Q1
$3.97K Sell
54
-1
-2% -$87 ﹤0.01% 1690
2022
Q4
$4.59K Sell
55
-11
-17% -$992 ﹤0.01% 1586
2022
Q3
$6K Buy
66
+1
+2% +$119 ﹤0.01% 1312
2022
Q2
$7K Buy
65
+12
+23% +$1.53K ﹤0.01% 1208
2022
Q1
$9K Hold
53
﹤0.01% 1136
2021
Q4
$9K Hold
53
﹤0.01% 1221
2021
Q3
$8K Hold
53
﹤0.01% 1219
2021
Q2
$13K Sell
53
-36
-40% -$9.45K ﹤0.01% 778
2021
Q1
$24K Buy
89
+36
+68% +$10.2K 0.01% 522
2020
Q4
$16K Hold
53
0.01% 538
2020
Q3
$13K Hold
53
0.01% 516
2020
Q2
$11K Sell
53
-4
-7% -$746 ﹤0.01% 541
2020
Q1
$10K Hold
57
﹤0.01% 562
2019
Q4
$10K Hold
57
﹤0.01% 697
2019
Q3
$7K Hold
57
﹤0.01% 713
2019
Q2
$7K Hold
57
﹤0.01% 686
2019
Q1
$7K Hold
57
﹤0.01% 695
2018
Q4
$7K Hold
57
﹤0.01% 693
2018
Q3
$7K Hold
57
﹤0.01% 705
2018
Q2
$5K Hold
57
﹤0.01% 761
2018
Q1
$3K Hold
57
﹤0.01% 830
2017
Q4
$3K Hold
57
﹤0.01% 881
2017
Q3
$3K Hold
57
﹤0.01% 823
2017
Q2
$4K Hold
57
﹤0.01% 787
2017
Q1
$3K Hold
57
﹤0.01% 823
2016
Q4
$2K Hold
57
﹤0.01% 984
2016
Q3
$3K Hold
57
﹤0.01% 839
2016
Q2
$3K Hold
57
﹤0.01% 818
2016
Q1
$3K Buy
+57
New +$2.2K ﹤0.01% 824

Other funds holding AMED

TCI Wealth Advisors's AMED Position: Q2 2023 in Review

TCI Wealth Advisors sold out of Amedisys (AMED) in Q2 2023, closing a stake of 54 shares — an estimated $3.97K sold.

TCI Wealth Advisors first reported a position in AMED in Q1 2016 and held it in 29 quarters. The position peaked at $24K in Q1 2021. 301 funds tracked by Wall St. Rank hold AMED as of Q2 2023.

  • TCI Wealth Advisors reported no remaining Amedisys position as of Q2 2023 after selling out during the quarter.
  • TCI Wealth Advisors sold 54 Amedisys shares in Q2 2023, an estimated $3.97K.
  • TCI Wealth Advisors first reported a position in Amedisys in Q1 2016 and held it in 29 quarters.
  • TCI Wealth Advisors's Amedisys position peaked at $24K in Q1 2021.
  • 301 funds tracked by Wall St. Rank held Amedisys as of Q2 2023.

Based on TCI Wealth Advisors's 13F filing for Q2 2023, filed 4 Aug 2023.